Globe Life
Globe Life's revenue rose 3.7% to $6.0 billion in fiscal 2025. Its net margin was 19.4%, up from 18.5% a year earlier. Free cash flow was $1.3 billion, down 5.8%. It paid out $967 million in dividends and buybacks, 77% of free cash flow. The diluted share count fell 8.0%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 13.5% a year and net income 8.7% a year, as buybacks cut the share count by 33%.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Globe Life yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Globe Life's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Globe Life's cash from operations minus depreciation in fiscal 2025 (free cash flow before spending to grow: capital spending was 4.8 times depreciation, which holds its free cash flow down) of $1.4B, net cash of −$2.2B at December 31, 2025 and 82 million diluted shares, from its filings. The scenarios are fitted to Globe Life: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 4.7% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 7% for a stable business (Life & Health Insurance); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $156.82
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Globe Life's earnings per share of $15.07 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 13.8×, the middle of Globe Life's own P/E today, its peers' median and its sector's median (the Financials median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 8%, 7% and 6%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $156.82
- Value at this multiple, against the last close
- —
- Globe Life's P/E at the last close
- 10.4×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| UnumUNM | $90.12 | $4.29 | 21.0× |
| CNO Financial GroupCNO | $54.20 | $2.91 | 18.6× |
| PrimericaPRI | $276.79 | $24.89 | 11.1× |
| Globe LifeGL | $156.82 | $15.07 | 10.4× |
| Brighthouse FinancialBHF | $44.83 | $12.53 | 3.6× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 161 | 207 | 185 | 250 | 459 |
| Debt incl. finance leases | 2,176 | 2,243 | 2,116 | 2,740 | 2,625 |
| Net debt (negative means net cash) | 2,015 | 2,036 | 1,931 | 2,489 | 2,166 |
| Net debt to EBITDA | 1.6x | 1.7x | 1.5x | 1.7x | 1.4x |
| Debt to equity | 1.1x | 0.6x | 0.5x | 0.5x | 0.4x |
| Interest coverage | 14.7x | 13.1x | 12.4x | 11.4x | 11.2x |
| Current ratio | — | — | — | — | — |
| Quick ratio | — | — | — | — | — |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Globe Life shares on the open market, and 12 insiders sold $79.9 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 23, 2026 | Michael Clay MajorsEVP - Chief Strategy Officer | Sold | 14,377 | $154.48 | $2.2 million | Form 4 |
| Sep 22, 2026 | Robert Edward HensleyEVP & Chief Investment Officer | Sold | 10,000 | $170.07 | $1.7 million | Form 4 |
| Aug 7, 2026 | Robert Brian MitchellEVP, General Counsel and CRO | Sold | 23,000 | $183.34 | $4.2 million | Form 4 |
| Jul 31, 2026 | James Matthew DardenCo-Chairman & CEO, Director | Sold | 50,000 | $182.44 | $9.1 million | Form 4 |
| Jul 30, 2026 | Thomas Peter KalmbachEVP & CFO | Sold | 21,000 | $180.06 | $3.8 million | Form 4 |
| Jul 29, 2026 | Michael Clay MajorsEVP - Chief Strategy Officer | Sold | 37,000 | $178.63 | $6.6 million | Form 4 |
| Jul 28, 2026 | Thomas Peter KalmbachEVP & CFO | Sold | 25,650 | $178.58 | $4.6 million | Form 4 |
| Jun 30, 2026 | Dolores L SkarjuneEVP and Chief Admin. Officer | Sold | 1,850 | $179.18 | $331,483 | Form 4 |
| Jun 25, 2026 | Cheryl AlstonDirector | Sold | 8,258 | $179.24 | $1.5 million | Form 4 |
| Jun 18, 2026 | Rebecca E ZornEVP & Chief Talent Officer | Sold | 2,000 | $170.10 | $340,200 | Form 4 |
| Jun 12, 2026 | Frank M SvobodaCo-Chairman & CEO, Director | Sold | 10,000 | $166.68 | $1.7 million | Form 4 |
| Jun 12, 2026 | Dolores L SkarjuneEVP and Chief Admin. Officer | Sold | 4,175 | $166.18 | $693,782 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | — | — | — |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
| Accruals ratio | −1.9% | −1.2% | −0.8% |
Compare
Put Globe Life side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Globe Life | FY25 | 3.7% | — | 20.9% | 16.0% | 1.4x | — | |
| Brighthouse Financial | FY25 | 43.2% | — | — | — | — | — | Compare |
| CNO Financial Group | FY25 | 0.8% | 12.3% | — | — | — | — | Compare |
| Primerica | FY25 | 6.6% | — | — | 34.5% | −0.2x | — | Compare |
| Unum | FY25 | 1.5% | — | 4.2% | 7.6% | 0.5x | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 3,935 | 4,156 | 4,304 | 4,528 | 4,738 | 5,112 | 5,227 | 5,448 | 5,778 | 5,994 |
| Revenue growth | 4.5% | 5.6% | 3.6% | 5.2% | 4.7% | 7.9% | 2.2% | 4.2% | 6.1% | 3.7% |
| Gross profit | 783 | 807 | 866 | 911 | 901 | 1,215 | 1,179 | 1,260 | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 787 | 821 | 871 | 920 | 905 | 1,227 | 1,186 | 1,265 | — | — |
| Net income | 550 | 1,454 | 702 | 761 | 732 | 1,031 | 894 | 971 | 1,071 | 1,161 |
| Diluted EPS (US$) | 4.49 | 12.22 | 6.09 | 6.83 | 6.82 | 9.99 | 9.04 | 10.07 | 11.94 | 14.07 |
| Diluted shares (millions) | 122 | 119 | 115 | 111 | 107 | 103 | 99 | 96 | 90 | 82 |
| Cash flow | ||||||||||
| Cash from operations | 1,399 | 1,429 | 1,278 | 1,364 | 1,476 | 1,438 | 1,422 | 1,482 | 1,402 | 1,396 |
| Capital expenditure | 25 | 20 | 45 | 42 | 42 | 38 | 28 | 50 | 71 | 142 |
| Free cash flow | 1,374 | 1,409 | 1,233 | 1,322 | 1,435 | 1,399 | 1,394 | 1,433 | 1,331 | 1,254 |
| Dividends paid | 67 | 69 | 71 | 74 | 78 | 80 | 80 | 84 | 86 | 86 |
| Share buybacks | 405 | 413 | 422 | 460 | 444 | 541 | 455 | 511 | 1,002 | 881 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 26 | 37 | 40 | 45 | 36 | 30 | 36 | 31 | 40 | 53 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 148 | 246 | 184 | 114 | 203 | 161 | 207 | 185 | 250 | 459 |
| Debt incl. finance leases | 1,400 | 1,465 | 1,672 | 1,657 | 1,923 | 2,176 | 2,243 | 2,116 | 2,740 | 2,625 |
| Total assets | 21,436 | 23,475 | 23,096 | 25,978 | 29,047 | 29,768 | 25,987 | 28,052 | 29,076 | 30,814 |
| Total liabilities | 16,869 | 17,244 | 17,680 | 18,683 | 20,276 | 21,125 | 22,037 | 23,565 | 23,771 | 24,839 |
| Shareholders' equity | 4,567 | 6,231 | 5,415 | 7,294 | 8,771 | 2,004 | 3,950 | 4,487 | 5,306 | 5,975 |
| Margins and ratios | ||||||||||
| Gross margin | 19.9% | 19.4% | 20.1% | 20.1% | 19.0% | 23.8% | 22.6% | 23.1% | — | — |
| Operating margin | 20.0% | 19.8% | 20.2% | 20.3% | 19.1% | 24.0% | 22.7% | 23.2% | — | — |
| Net margin | 14.0% | 35.0% | 16.3% | 16.8% | 15.4% | 20.2% | 17.1% | 17.8% | 18.5% | 19.4% |
| Free cash flow margin | 34.9% | 33.9% | 28.6% | 29.2% | 30.3% | 27.4% | 26.7% | 26.3% | 23.0% | 20.9% |
| Return on capital | 10.0% | 12.4% | 9.8% | 9.6% | 7.7% | 13.7% | 19.2% | 16.6% | 16.5% | 16.0% |
| Return on equity | 12.8% | 26.9% | 12.1% | 12.0% | 9.1% | 19.1% | 30.1% | 23.0% | 21.9% | 20.6% |
| Return on assets | 2.7% | 6.5% | 3.0% | 3.1% | 2.7% | 3.5% | 3.2% | 3.6% | 3.8% | 3.9% |
| Net debt to EBITDA | 1.6x | 1.5x | 1.7x | 1.6x | 1.9x | 1.6x | 1.7x | 1.5x | 1.7x | 1.4x |